These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11685801)

  • 1. The kinetics of hepatitis C virus infection.
    Zeuzem S
    Clin Liver Dis; 2001 Nov; 5(4):917-30. PubMed ID: 11685801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of hepatitis C virus infection.
    Zeuzem S; Herrmann E
    Ann Hepatol; 2002; 1(2):56-63. PubMed ID: 15115969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus: kinetics and quasispecies evolution during anti-viral therapy.
    Zeuzem S
    Forum (Genova); 2000; 10(1):32-42. PubMed ID: 10717256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus kinetics.
    Herrmann E; Neumann AU; Schmidt JM; Zeuzem S
    Antivir Ther; 2000 Jun; 5(2):85-90. PubMed ID: 10971860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
    Herrmann E; Lee JH; Marinos G; Modi M; Zeuzem S
    Hepatology; 2003 Jun; 37(6):1351-8. PubMed ID: 12774014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
    Sherman KE; Shire NJ; Rouster SD; Peters MG; James Koziel M; Chung RT; Horn PS
    Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection.
    McGovern BH; Nagami EH; Birch CE; Bowen MJ; Reyor LL; Chung RT; Kim AY
    J Infect Dis; 2009 Sep; 200(6):877-81. PubMed ID: 19673649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.
    Neumann AU; Lam NP; Dahari H; Gretch DR; Wiley TE; Layden TJ; Perelson AS
    Science; 1998 Oct; 282(5386):103-7. PubMed ID: 9756471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept.
    Pardo-Yules B; Gallego-Durán R; Eslam M; García-Collado C; Grande L; Paradas C; Morillo R; Dorantes B; Romero-Gómez M
    Rev Esp Enferm Dig; 2011 Dec; 103(12):619-25. PubMed ID: 22217345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding telaprevir improves cure rate in patient with HCV infection.
    AIDS Patient Care STDS; 2010 Dec; 24(12):807. PubMed ID: 21188771
    [No Abstract]   [Full Text] [Related]  

  • 12. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
    Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
    Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
    Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A perspective on modelling hepatitis C virus infection.
    Guedj J; Rong L; Dahari H; Perelson AS
    J Viral Hepat; 2010 Dec; 17(12):825-33. PubMed ID: 20723038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin.
    Carlsson T; Weiland O; Reichard O
    Scand J Gastroenterol; 2002 Oct; 37(10):1228-34. PubMed ID: 12408530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.
    da Silva LC; Bassit L; Ono-Nita SK; Pinho JR; Nishiya A; Madruga CL; Carrilho FJ
    J Gastroenterol; 2002; 37(9):732-6. PubMed ID: 12375147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.
    Knop V; Teuber G; Klinker H; Möller B; Rasenack J; Hinrichsen H; Gerlach T; Spengler U; Buggisch P; Neumann K; Sarrazin C; Zeuzem S; Berg T
    Ann Hepatol; 2013; 12(2):190-8. PubMed ID: 23396729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
    Pilli M; Zerbini A; Penna A; Orlandini A; Lukasiewicz E; Pawlotsky JM; Zeuzem S; Schalm SW; von Wagner M; Germanidis G; Lurie Y; Esteban JI; Haagmans BL; Hezode C; Lagging M; Negro F; Homburger Y; Neumann AU; Ferrari C; Missale G;
    Gastroenterology; 2007 Oct; 133(4):1132-43. PubMed ID: 17919489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.